Tirzepatide with BPC-157 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Tirzepatide with BPC-157 is the same pairing idea as the semaglutide version.
Evidence grade for Tirzepatide with BPC-157: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, none stating how many people. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 0 people given it
7 effects reported, 4 unwanted, 3 wanted, by people using it, not a trial
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Same idea as the last one with a stronger drug on the front half. Tirzepatide takes a fifth of body weight off most people who take it, and that makes the muscle worry sharper. The peptide added on top has no proper human data and cannot legally be compounded in the US.
What people take it for
- Losing weight without losing muscle.
- Less stomach trouble.
- Healing joints while dieting.
What studies in people showed
No study of the two together, in any animal. The tirzepatide half is strong. In SURMOUNT-1, people lost 20.9 percent of their body weight on the top dose over 72 weeks. The dummy shot group lost 3.1 percent. And 57 percent of the drug group lost a fifth of their body weight or more. The BPC-157 half is five small studies with fewer than 110 people, none using a shot under the skin. No study in any species has measured muscle loss during dieting with it. One more thing worth knowing. The only published lab test of tirzepatide mixed with something else looked at B12 versions and found a reaction product nobody can explain. That was a vitamin. Nobody has run the same test on tirzepatide mixed with a research peptide.
What people report
Reports, not study results
The good
- Less stomach discomfort after adding it, though those side effects fade on their own.
- Better joint comfort.
- A feeling of holding more muscle, which nobody in these reports has measured.
The bad
- No difference at all.
- In the US, BPC-157 is not allowed in compounded products, so a premixed vial is not legal on that ingredient.
- Worry about what is in the vial, after the published impurity work on compounded tirzepatide mixes.
- The two do not share a schedule.
Where these come from: Patient and peptide forums plus clinic write-ups. People talking, and heavily confounded because incretin side effects fade by themselves.
My bottom line
Tirzepatide is a serious drug that works. When something is working, you keep the number of unknowns low. Lift weights and eat protein instead.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Tirzepatide with BPC-157 has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing weightno headcount stated · 1 study
What people using it report
Real people telling you what happened to them. Nobody checked it, and the people who post are not a fair sample, so it cannot prove anything works. It is still the best guide on this page to what people actually do with Tirzepatide with BPC-157, what they expect, and what goes wrong. The full account, including the negative reports, is below.
35 of the 36 indexed goals have no study of any kind behind Tirzepatide with BPC-157
No study in people, animals or cells on this page reports a result for these. That does not prove Tirzepatide with BPC-157 does nothing for them. It does mean anything you have heard about Tirzepatide with BPC-157 and one of these did not come from a study cited here.
Show full evidence
What is Tirzepatide with BPC-157?
Tirzepatide with BPC-157 is the same pairing idea as the semaglutide version. One side has a bigger weight loss effect. The other side is just as empty. Tirzepatide 15 mg cut weight by 20.9% on average at 72 weeks. BPC-157 has five studies in people with under 110 people in all, and none gave it the way it is used here. Nobody has studied the pair. US pharmacies are not allowed to make BPC-157.
Tirzepatide works so well that the muscle question gets sharper than with semaglutide. In the big SURMOUNT-1 study, 57% of people on 15 mg lost 20% or more of their body weight over 72 weeks. On the dummy shot it was 3%. Losing a fifth of your body weight in eighteen months means losing a real amount of muscle along with fat. That fear is what this stack is sold on.
What gets added is a peptide with no evidence that fits. FDA staff counted five studies of BPC-157 in people, with fewer than 110 people in all. Two were only conference summaries. None lasted more than two weeks, and none gave it as a shot under the skin. A 2025 review found 35 of its 36 studies were in animals or in a dish. No study in people or animals has measured muscle with this peptide while eating less.
There is a second reason this pairing gets its own page. It is about where the drug comes from. Pharmacy-made tirzepatide already has one published quality finding. Lab tests of tirzepatide premixed with B12 found a new unwanted chemical in many products. It forms when the peptide reacts with some forms of B12, and nobody knows what it does in people. That was an approved peptide mixed with a vitamin. An approved peptide mixed with an unapproved research chemical raises the same kind of question. And nobody has tested that at all.
In practice the two are almost always taken as separate shots. Tirzepatide is weekly, and BPC-157 is said to be gone in under half an hour. When a seller premixes them, one of the two is on the wrong timing by design.
How does Tirzepatide with BPC-157 work?
Tirzepatide copies two gut hormones, GIP and GLP-1. It turns down appetite and slows how fast the stomach empties. In rats and mice, BPC-157 seems to help new blood vessels grow and to change growth and swelling signals. No published work looks at how the two affect each other. That includes whether the repair peptide changes how tirzepatide gets absorbed. That matters, because the way tirzepatide is absorbed is what lets it be a weekly shot.
What have studies in people found about Tirzepatide with BPC-157?
One half has a big study in people. The other has five small studies, none given the way people use it. The pair has nothing.
- Tirzepatide: 20.9% average weight loss on 15 mg at 72 weeks, against 3.1% on a dummy shot.
- BPC-157: fewer than 110 people across five studies. None gave it as a shot under the skin, and none lasted more than two weeks.
- Keeping muscle with BPC-157 during weight loss: never measured, in people or animals.
- Premixing tirzepatide with something else: the one published lab test, of a B12 premix, found a new chemical made by a reaction.
- The pair: no published study in people or animals, and no listed trial.
What this does not tell you: No study has looked at how the two affect each other, either way. And the FDA found BPC-157 products mislabelled on the market. So even how much of the second ingredient is in a given vial is not known.
What do people who took Tirzepatide with BPC-157 report?
This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.
- Less stomach discomfort after adding the repair peptide. But these side effects fade on their own, so it is hard to tell.
- Joints feeling better, which is the usual report for BPC-157 alone.
- A feeling of holding on to more muscle. Nobody in these reports measured it.
- No difference at all.
- Worry about what is in the vial, after the published lab finding on pharmacy-made tirzepatide mixes.
Sources: Forums including r/peptides and r/tirzepatidecompound, and clinic write-ups. Uncontrolled self-reports, heavily confounded by the natural course of incretin side effects.
The state of the research
How well tirzepatide works is what makes the rest of this page matter. A drug that takes a fifth of body weight off most people who take it is a serious treatment. With a serious treatment, you want to keep the other moving parts few and known. Adding an unapproved peptide from an unchecked source to a plan that is already working swaps a known thing for an unknown one.
On muscle: the answers with evidence are lifting weights and eating enough protein. Both are free, and neither has a supply problem. That is not a clever line. It is all the evidence there is.
The evidence, in charts
Fig. 1a · how many people
1study in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
1 of 4 sources here is a study in people. The rest are not.
- Study in people · done in people125%
- Lab (cells in a dish) · cells or tissue125%
- Review of studies · sums up other studies250%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 3 different years, 2022 to 2026, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Blend
- Molecule weight
- Not on file
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Not defined for the pairing. One component persists across the full interval and the other disappears almost at once, which is why no shared schedule exists.
No amino acid sequence is on file for Tirzepatide with BPC-157, which is expected: a blend is not built from amino acids.
Fig. 6 · what is in the vial
We cannot show how much of each is in this blend
Sellers do not agree on a vial size for Tirzepatide with BPC-157, so nobody outside can know how much of each ingredient is in it. Splitting the bar evenly would make up the very number this page is here to question.
- TirzepatideStrong. At least two finished studies in people, and at least 1,000 people who took it. 9 completed trials, 22,802 people given it.amount not stated
- BPC-157Limited. People have taken it in a published study, but fewer than 100 of them. 3 completed trials, 31 people given it.amount not stated
Ingredient list from the product labels we have. Amounts are what the label says is in the vial, never a dose.
The studies we cite
- Study in people2022Tirzepatide Once Weekly for the Treatment of Obesity
Tirzepatide on its own causes very large weight loss, and this is the study behind that. Adults took a weekly shot at one of three strengths, or a dummy shot, for about 17 months. Average weight fell 15.0%, 19.5% and 20.9% as the dose went up, against 3.1% on the dummy. On the top dose, 57 in every 100 lost a fifth or more of their body weight, against 3 in 100. Stomach and bowel upsets were the usual complaint. Tirzepatide alone, with nothing mixed in.
SURMOUNT-1. Mean weight change at 72 weeks of 15.0%, 19.5% and 20.9% on 5, 10 and 15 mg weekly against 3.1% on placebo, with 57% of the 15 mg group losing 20% or more of body weight against 3% on placebo. Gastrointestinal events were the most common adverse events. Tirzepatide alone.
- Review of studies2026FDA briefing document on BPC-157 for the July 2026 PCAC meeting
FDA staff counted every study of BPC-157 in people. They found five, with fewer than 110 people in all. Two were only short conference summaries. None gave it for longer than two weeks. None gave it as a shot under the skin, which is how people use it. Staff found no good human data, and they found products on the market with the wrong label.
FDA staff counted five published human studies of BPC-157 totalling fewer than 110 subjects, two of them meeting abstracts only, none dosing longer than two weeks, and none giving the peptide by subcutaneous injection. Staff found no adequate human data and mislabelled products in the market.
- Review of studies2025Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
This review looked hard for BPC-157 studies and found almost none in people. Out of 36 studies it kept, 35 were in animals or in a dish. The one study in people looked back at 12 patients with knee pain who had the peptide put into the knee. 7 of the 12 said the pain eased for more than six months. There was no comparison group. The review says the peptide lasts under 30 minutes in the body.
544 articles screened, 36 included, of which 35 were preclinical and one was clinical. That single clinical study was a retrospective series in which 7 of 12 patients reported relief beyond six months after intra-articular BPC-157 for unspecified chronic knee pain. The review puts the half-life at under 30 minutes.
- Lab (cells in a dish)2026A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications
This is a lab test, not a study in people. Pharmacy-made tirzepatide premixed with B12 was tested, and a new unwanted chemical turned up in many products. It forms when the peptide reacts with some forms of B12. Nobody knows what it does in people. The authors work for Eli Lilly, which sells branded tirzepatide, and the paper says so. It is the closest evidence on tirzepatide sharing a vial with something else. Here that was a vitamin, not a research peptide.
Analytical testing of compounded tirzepatide premixed with B12 found a widespread, previously unidentified impurity formed by a chemical reaction between the peptide and certain B12 analogues, with clinical effects stated to be unknown. Authored by Eli Lilly employees, a disclosed conflict. It is the nearest published evidence on what happens when tirzepatide shares a vial with another substance, and the other substance there was a vitamin rather than a research peptide.
Where to buy Tirzepatide with BPC-157
No seller we track lists Tirzepatide with BPC-157 yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has Tirzepatide with BPC-157 been tested in people?
Yes. 0 people given it across 1 completed trial cited here, 0 of which found nothing. Tirzepatide with BPC-157 is the same pairing idea as the semaglutide version.
What is the Tirzepatide with BPC-157 dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 0 people given it
Is Tirzepatide with BPC-157 FDA-approved?
Tirzepatide is approved. BPC-157 is not approved. FDA staff reviewed it in July 2026 and found no adequate human data, and pharmacies are not allowed to mix it. The combination has never been reviewed.
Has the combination been tested?
No, in people or animals. There is no data on how the two affect each other, either way.
Will BPC-157 stop me losing muscle?
No study in people or animals has measured that. What does have evidence is lifting weights and eating enough protein.
Is a premixed tirzepatide and BPC-157 vial legal in the US?
No. BPC-157 is not approved and US pharmacies are not allowed to make it. So the second ingredient makes the mix unlawful, whatever the first one is.
Is there a chemistry risk in premixing?
There is one published warning. Lab tests of pharmacy-made tirzepatide premixed with B12 found a new unwanted chemical in many products. It forms when the peptide reacts with some forms of B12. Nobody has run the same test on tirzepatide premixed with a research peptide.
What does tirzepatide do on its own?
In the SURMOUNT-1 study, people on 15 mg lost 20.9% of their weight on average at 72 weeks, against 3.1% on a dummy shot. 57% of that group lost 20% or more of their body weight.